A phase 1 trial evaluating CDX-1140 with or without anti-PD-1 (pembrolizumab) or FMS-related tyrosine kinase 3 ligand (Flt3L) (CDX-301) in advanced cancers is ongoing (NCT03329950). Here, FLT3LG is linked to cancer.